SATB1 and p16 Expression and Prognostic Value in Croatian Hodgkin Lymphoma Patients: A Unicentric Study
Abstract
:1. Introduction
2. Materials and Methods
2.1. Tissue Samples of Patients
2.2. Immunohistochemical Staining
2.3. Transcriptomic Analysis
2.4. Statistical Methods
3. Results
3.1. SATB1 Expression Associated with a More Favorable Prognosis
3.2. p16 Expression Does Not Seem to Change Long Term Prognosis
3.3. SATB1+/p16- Patients Have the Most Favorable Prognosis
3.4. Analysis of Publicly Available Transcriptomic Datasets
4. Discussion
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Alaggio, R.; Amador, C.; Anagnostopoulos, I.; Attygalle, A.D.; de Oliveira Araujo, I.B.; Berti, E.; Bhagat, G.; Borges, A.M.; Boyer, D.; Calaminici, M.; et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. Leukemia 2022, 36, 1720–1748. [Google Scholar] [CrossRef] [PubMed]
- Liu, Y.; van den Berg, A.; Veenstra, R.; Rutgers, B.; Nolte, I.; van Imhoff, G.; Visser, L.; Diepstra, A. PML Nuclear Bodies and SATB1 Are Associated with HLA Class I Expression in EBV+ Hodgkin Lymphoma. PLoS ONE 2013, 8, e72930. [Google Scholar] [CrossRef] [PubMed]
- Harris, N.L. Hodgkin’s disease: Classification and differential diagnosis. Mod. Pathol. 1999, 12, 159–175. [Google Scholar] [PubMed]
- Zukerberg, L.R.; Collins, A.B.; Ferry, J.A.; Harris, N.L. Coexpression of CD15 and CD20 by Reed-Sternberg cells in Hodgkin’s disease. Am. J. Pathol. 1991, 139, 475–483. [Google Scholar] [PubMed]
- Schmid, C.; Pan, L.; Diss, T.; Isaacson, P.G. Expression of B-cell antigens by Hodgkin’s and Reed-Sternberg cells. Am. J. Pathol. 1991, 139, 701–707. [Google Scholar] [PubMed]
- Skinnider, B.F.; Mak, T.W. The role of cytokines in classical Hodgkin lymphoma. Blood 2002, 99, 4283–4297. [Google Scholar] [CrossRef] [PubMed]
- Campo, E.; Jaffe, E.S.; Cook, J.R.; Quintanilla-Martinez, L.; Swerdlow, S.H.; Anderson, K.C.; Brousset, P.; Cerroni, L.; de Leval, L.; Dirnhofer, S.; et al. The International Consensus Classification of Mature Lymphoid Neoplasms: A report from the Clinical Advisory Committee. Blood 2022, 140, 1229–1253. [Google Scholar] [CrossRef] [PubMed]
- Voorhees, T.J.; Beaven, A.W. Therapeutic Updates for Relapsed and Refractory Classical Hodgkin Lymphoma. Cancers 2020, 12, 2887. [Google Scholar] [CrossRef]
- Al-Salam, S.; Awwad, A.; Sudhadevi, M.; Daoud, S.; Nagelkerke, N.J.D.; Castella, A.; Chong, S.M.; Alashari, M. Epstein-Barr virus infection correlates with the expression of COX-2, p16(INK4A) and p53 in classic Hodgkin lymphoma. Int. J. Clin. Exp. Pathol. 2013, 6, 2765–2777. [Google Scholar]
- Jankowska-Konsur, A.; Kobierzycki, C.; Reich, A.; Grzegrzolka, J.; Bieniek, A.; Dziegiel, P. Expression of SATB1, MTI/II and Ki-67 in Mycosis Fungoides. Anticancer Res. 2016, 36, 189–197. [Google Scholar] [CrossRef]
- Glatzel-Plucińska, N.; Piotrowska, A.; Dzięgiel, P.; Podhorska-Okołów, M. The Role of SATB1 in Tumour Progression and Metastasis. Int. J. Mol. Sci. 2019, 20, 4156. [Google Scholar] [CrossRef] [PubMed]
- Fredholm, S.; Willerslev-Olsen, A.; Met, Ö.; Kubat, L.; Gluud, M.; Mathiasen, S.L.; Friese, C.; Blümel, E.; Petersen, D.L.; Hu, T.; et al. SATB1 in Malignant T Cells. J. Investig. Dermatol. 2018, 138, 1805–1815. [Google Scholar] [CrossRef] [PubMed]
- Grzanka, D.; Gagat, M.; Izdebska, M.; Marszałek, A. Expression of special AT-rich sequence-binding protein 1 is an independent prognostic factor in cutaneous T-cell lymphoma. Oncol. Rep. 2015, 33, 250–266. [Google Scholar] [CrossRef] [PubMed]
- Wang, Y.; Gu, X.; Zhang, G.; Wang, L.; Wang, T.; Zhao, Y.; Zhang, X.; Zhou, Y.; Kadin, M.; Tu, P. SATB1 overexpression promotes malignant T-cell proliferation in cutaneous CD30+ lymphoproliferative disease by repressing p21. Blood 2014, 123, 3452–3461. [Google Scholar] [CrossRef] [PubMed]
- Frömberg, A.; Engeland, K.; Aigner, A. The Special AT-rich Sequence Binding Protein 1 (SATB1) and its role in solid tumors. Cancer Lett. 2018, 417, 96–111. [Google Scholar] [CrossRef] [PubMed]
- Yi, H.; Wei, Y.; Chen, J.-J. Expression of SATB1 is a prognostic indicator for survival in diffuse large B-cell lymphoma patients. Eur. Rev. Med. Pharmacol. Sci. 2022, 26, 382–390. [Google Scholar] [PubMed]
- Irshaid, F.; Tarawneh, K.; Alshdefat, A.; Dilmi, F.; Jaran, A.; Al-Hadithi, R.; Al-Khatib, A. Loss of P16 Protein Expression and Its Association with Epstein-Barr Virus LMP-1 Expression in Hodgkin’s Lymphoma. Iran. J. Cancer Prev. 2013, 6, 78–84. [Google Scholar]
- Caliò, A.; Zamò, A.; Ponzoni, M.; Zanolin, M.E.; Ferreri, A.J.M.; Pedron, S.; Montagna, L.; Parolini, C.; Fraifeld, V.E.; Wolfson, M.; et al. Cellular Senescence Markers p16INK4a and p21CIP1/WAF Are Predictors of Hodgkin Lymphoma Outcome. Clin. Cancer Res. 2015, 21, 5164–5172. [Google Scholar] [CrossRef] [PubMed]
- Inoue, K.; Fry, E.A. Aberrant expression of p16INK4a in human cancers—A new biomarker? Cancer Rep. Rev. 2018, 2. [Google Scholar] [CrossRef]
- Morente, M.M.; Piris, M.A.; Abraira, V.; Acevedo, A.; Aguilera, B.; Bellas, C.; Fraga, M.; Garcia-Del-Moral, R.; Gomez-Marcos, F.; Menarguez, J.; et al. Adverse clinical outcome in Hodgkin’s disease is associated with loss of retinoblastoma protein expression, high Ki67 proliferation index, and absence of Epstein-Barr virus-latent membrane protein 1 expression. Blood 1997, 90, 2429–2436. [Google Scholar]
- Lister, T.A.; Crowther, D.; Sutcliffe, S.B.; Glatstein, E.; Canellos, G.P.; Young, R.C.; Rosenberg, S.A.; Coltman, C.A.; Tubiana, M. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin’s disease: Cotswolds meeting. J. Clin. Oncol. 1989, 7, 1630–1636. [Google Scholar] [CrossRef]
- Oken, M.M.; Creech, R.H.; Tormey, D.C.; Horton, J.; Davis, T.E.; McFadden, E.T.; Carbone, P.P. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am. J. Clin. Oncol. 1982, 5, 649–655. [Google Scholar] [CrossRef] [PubMed]
- Eichenauer, D.A.; Aleman, B.M.P.; André, M.; Federico, M.; Hutchings, M.; Illidge, T.; Engert, A.; Ladetto, M.; ESMO Guidelines Committee. Hodgkin lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 2018, 29, iv19–iv29. [Google Scholar] [CrossRef] [PubMed]
- Hasenclever, D.; Diehl, V. A prognostic score for advanced Hodgkin’s disease. International Prognostic Factors Project on Advanced Hodgkin’s Disease. N. Engl. J. Med. 1998, 339, 1506–1514. [Google Scholar] [CrossRef] [PubMed]
- Remmele, W.; Stegner, H.E. Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue. Pathologe 1987, 8, 138–140. [Google Scholar] [PubMed]
- Chen, Z.; Li, Z.; Li, W.; Zong, Y.; Zhu, Y.; Miao, Y.; Xu, Z. SATB1 Promotes Pancreatic Cancer Growth and Invasion Depending on MYC Activation. Dig. Dis. Sci. 2015, 60, 3304–3317. [Google Scholar] [CrossRef] [PubMed]
- Edgar, R.; Domrachev, M.; Lash, A.E. Gene Expression Omnibus: NCBI gene expression and hybridization array data repository. Nucleic Acids Res. 2002, 30, 207–210. [Google Scholar] [CrossRef] [PubMed]
- Reich, M.; Liefeld, T.; Gould, J.; Lerner, J.; Tamayo, P.; Mesirov, J.P. GenePattern 2.0. Nat. Genet. 2006, 38, 500–501. [Google Scholar] [CrossRef] [PubMed]
- Subramanian, A.; Tamayo, P.; Mootha, V.K.; Mukherjee, S.; Ebert, B.L.; Gillette, M.A.; Paulovich, A.; Pomeroy, S.L.; Golub, T.R.; Lander, E.S.; et al. Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. USA 2005, 102, 15545–15550. [Google Scholar] [CrossRef]
- Barbie, D.A.; Tamayo, P.; Boehm, J.S.; Kim, S.Y.; Moody, S.E.; Dunn, I.F.; Schinzel, A.C.; Sandy, P.; Meylan, E.; Scholl, C.; et al. Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature 2009, 462, 108–112. [Google Scholar] [CrossRef] [PubMed]
- Hammer, Ø.; Harper, D.A.T.; Ryan, P.D. PAST: Paleontological statistics software package for education and data analysis. Palaeontol. Electron. 2001, 4, 1–9. [Google Scholar]
- Péricart, S.; Tosolini, M.; Gravelle, P.; Rossi, C.; Traverse-Glehen, A.; Amara, N.; Franchet, C.; Martin, E.; Bezombes, C.; Laurent, G.; et al. Profiling Immune Escape in Hodgkin’s and Diffuse large B-Cell Lymphomas Using the Transcriptome and Immunostaining. Cancers 2018, 10, 415. [Google Scholar] [CrossRef] [PubMed]
- Munir, F.; Hardit, V.; Sheikh, I.N.; AlQahtani, S.; He, J.; Cuglievan, B.; Hosing, C.; Tewari, P.; Khazal, S. Classical Hodgkin Lymphoma: From Past to Future—A Comprehensive Review of Pathophysiology and Therapeutic Advances. Int. J. Mol. Sci. 2023, 24, 10095. [Google Scholar] [CrossRef] [PubMed]
- Morton, L.M.; Wang, S.S.; Devesa, S.S.; Hartge, P.; Weisenburger, D.D.; Linet, M.S. Lymphoma incidence patterns by WHO subtype in the United States, 1992–2001. Blood 2006, 107, 265–276. [Google Scholar] [CrossRef]
- Moscona-Nissan, A.; Mancilla-Osuna, M.F.; Bardán-Duarte, A.; Rendón-Macías, M.E. Classical Hodgkin lymphoma histologic subtypes distribution among geographical regions and correlation with Human Development Index. Health Sci. Rev. 2023, 9, 100117. [Google Scholar] [CrossRef]
- Shamoon, R.P.; Ali, M.D.; Shabila, N.P. Overview and outcome of Hodgkin’s Lymphoma: Experience of a single developing country’s oncology centre. PLoS ONE 2018, 13, e0195629. [Google Scholar] [CrossRef]
- Bazzeh, F.; Rihani, R.; Howard, S.; Sultan, I. Comparing adult and pediatric Hodgkin lymphoma in the Surveillance, Epidemiology and End Results Program, 1988–2005: An analysis of 21,734 cases. Leuk. Lymphoma 2010, 51, 2198–2207. [Google Scholar] [CrossRef] [PubMed]
- Luo, X.-D.; Yang, S.-J.; Wang, J.-N.; Tan, L.; Liu, D.; Wang, Y.-Y.; Zheng, R.-H.; Wu, X.-H.; Xu, L.-H.; Tan, H. Downregulation of SATB1 increases the invasiveness of Jurkat cell via activation of the WNT/β-catenin signaling pathway in vitro. Tumor Biol. 2015, 37, 7413–7419. [Google Scholar] [CrossRef] [PubMed]
- Li, Y.; Wang, J.; Yu, M.; Wang, Y.; Zhang, H.; Yin, J.; Li, Z.; Li, T.; Yan, H.; Li, F.; et al. SNF5 deficiency induces apoptosis resistance by repressing SATB1 expression in Sézary syndrome. Leuk. Lymphoma 2018, 59, 2405–2413. [Google Scholar] [CrossRef]
- Selinger, C.I.; Cooper, W.A.; Al-Sohaily, S.; Mladenova, D.N.; Pangon, L.; Kennedy, C.W.; McCaughan, B.C.; Stirzaker, C.; Kohonen-Corish, M.R. Loss of Special AT-Rich Binding Protein 1 Expression is a Marker of Poor Survival in Lung Cancer. J. Thorac. Oncol. 2011, 6, 1179–1189. [Google Scholar] [CrossRef]
- Wang, Y.; Su, M.; Zhou, L.L.; Tu, P.; Zhang, X.; Jiang, X.; Zhou, Y. Deficiency of SATB1 expression in Sézary cells causes apoptosis resistance by regulating FasL/CD95L transcription. Blood 2011, 117, 3826–3835. [Google Scholar] [CrossRef] [PubMed]
- Luo, X.; Xu, L.; Wu, X.; Tan, H.; Liu, L. Decreased SATB1 expression promotes AML cell proliferation through NF-κB activation. Cancer Cell Int. 2019, 19, 134. [Google Scholar] [CrossRef] [PubMed]
- Hu, S.; Xu-Monette, Z.Y.; Balasubramanyam, A.; Manyam, G.C.; Visco, C.; Tzankov, A.; Liu, W.-M.; Miranda, R.N.; Zhang, L.; Montes-Moreno, S.; et al. CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: A report from the International DLBCL Rituximab-CHOP Consortium Program Study. Blood 2013, 121, 2715–2724. [Google Scholar] [CrossRef] [PubMed]
- Jardin, F. NFkB Pathway and Hodgkin Lymphoma. Biomedicines 2022, 10, 2153. [Google Scholar] [CrossRef] [PubMed]
- Rassidakis, G.Z.; Medeiros, L.J.; Vassilakopoulos, T.P.; Viviani, S.; Bonfante, V.; Nadali, G.; Herling, M.; Angelopoulou, M.K.; Giardini, R.; Chilosi, M.; et al. BCL-2 expression in Hodgkin and Reed-Sternberg cells of classical Hodgkin disease predicts a poorer prognosis in patients treated with ABVD or equivalent regimens. Blood 2002, 100, 3935–3941. [Google Scholar] [CrossRef]
- Herrera, A.; Fredholm, S.; Cheng, A.; Mimitou, E.P.; Seffens, A.; Bar-Natan, M.; Sun, A.; Latkowski, J.-A.; Willerslew-Olsen, A.; Buus, T.B.; et al. Low SATB1 Expression Promotes IL-5 and IL-9 Expression in Sezary Syndrome. J. Investig. Dermatol. 2020, 140, 713–716. [Google Scholar] [CrossRef] [PubMed]
- de la Cruz-Merino, L.; Lejeune, M.; Nogales Fernández, E.; Henao Carrasco, F.; Grueso López, A.; Illescas Vacas, A.; Pulla, M.P.; Callau, C.; Álvaro, T. Role of immune escape mechanisms in Hodgkin’s lymphoma development and progression: A whole new world with therapeutic implications. Clin. Dev. Immunol. 2012, 2012, 756353. [Google Scholar] [CrossRef]
- Irshaid, F.; Jaran, A.; Dilmi, F.; Tarawneh, K.; Hadeth, R.; Khatib, A.A. Prevalence of Epstein-Barr Virus Latent Membrane Protein-1 in Jordanian Patients with Hodgkin’s Lymphoma and Non-Hodgkin’s Lymphoma. J. Biol. Sci. 2010, 10, 507–513. [Google Scholar] [CrossRef]
- Zhao, P.; Lu, Y.; Liu, L.; Zhong, M. Aberrant Expression of ID2 protein and its correlation with EBV-LMP1 and P16(INK4A) in Classical Hodgkin Lymphoma in China. BMC Cancer 2008, 8, 379. [Google Scholar] [CrossRef]
- Gopas, J.; Stern, E.; Zurgil, U.; Ozer, J.; Ben-Ari, A.; Shubinsky, G.; Braiman, A.; Sinay, R.; Ezratty, J.; Dronov, V.; et al. Reed-Sternberg cells in Hodgkin’s lymphoma present features of cellular senescence. Cell Death Dis. 2016, 7, e2457. [Google Scholar] [CrossRef]
- Lebok, P.; Roming, M.; Kluth, M.; Koop, C.; Özden, C.; Taskin, B.; Hussein, K.; Lebeau, A.; Witzel, I.; Wölber, L.; et al. p16 overexpression and 9p21 deletion are linked to unfavorable tumor phenotype in breast cancer. Oncotarget 2016, 7, 81322–81331. [Google Scholar] [CrossRef] [PubMed]
- Zhou, N.; Gu, Q. Prognostic and clinicopathological value of p16 protein aberrant expression in colorectal cancer A PRISMA-compliant Meta-analysis. Medicine 2018, 97, e0195. [Google Scholar] [CrossRef] [PubMed]
number of patients | 86 |
age [years, median], IQR [years] | 41, 28 to 55 |
sex [n, %] | |
female | 47, 54.7% |
male | 39, 45.3% |
histological type [n, %] | |
mixed cellularity | 20, 23.3% |
nodular sclerosis | 60, 69.8% |
other | 6, 6.9% |
clinical stage [n, %] | |
I | 9, 10.5% |
II | 42, 48.8% |
III | 16, 18.6% |
IV | 19, 22.1% |
+ extranodal localization [n, %] | 15, 17.4% |
+ B symptoms [n, %] | 54, 62.3% |
+ bulky disease [n, %] | 15, 17.4% |
EORCT [for stages I and II, n, %] | |
0 | 13, 25.5% |
1 | 15, 29.4% |
2 | 16, 31.4% |
3 | 7, 13.7% |
GHSG [for stages I & II, n, %] | |
0 | 12, 23.5% |
1 | 15, 29.4% |
2 | 18, 35.3% |
3 | 6, 11.7% |
IPS [for stages III and IV, n, %] | |
1 | 8, 22.9% |
2 | 10, 28.6% |
3 | 12, 34.3% |
4 | 2, 5.7% |
5 | 3, 8.6% |
ECOG [n, %] | |
0 | 64, 74.4% |
1 | 18, 20.9% |
2 | 4, 4.7% |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Vicelić Čutura, L.; Vujčić, M.; Galušić, D.; Blaslov, V.; Petrić, M.; Miljak, A.; Lozić, M.; Benzon, B.; Vukojević, K.; Bubić, T.; et al. SATB1 and p16 Expression and Prognostic Value in Croatian Hodgkin Lymphoma Patients: A Unicentric Study. Cells 2024, 13, 1323. https://doi.org/10.3390/cells13161323
Vicelić Čutura L, Vujčić M, Galušić D, Blaslov V, Petrić M, Miljak A, Lozić M, Benzon B, Vukojević K, Bubić T, et al. SATB1 and p16 Expression and Prognostic Value in Croatian Hodgkin Lymphoma Patients: A Unicentric Study. Cells. 2024; 13(16):1323. https://doi.org/10.3390/cells13161323
Chicago/Turabian StyleVicelić Čutura, Lučana, Milan Vujčić, Davor Galušić, Viktor Blaslov, Marija Petrić, Antonija Miljak, Mirela Lozić, Benjamin Benzon, Katarina Vukojević, Toni Bubić, and et al. 2024. "SATB1 and p16 Expression and Prognostic Value in Croatian Hodgkin Lymphoma Patients: A Unicentric Study" Cells 13, no. 16: 1323. https://doi.org/10.3390/cells13161323